A PSMA-Targeted, CD2-Costimulating T-Cell Engager with Strong Preclinical Efficacy & a Favorable GLP Toxicology Profile
- PSMA is highly expressed in prostate cancer, and single‑cell RNA sequencing of metastatic tumor‑infiltrating lymphocytes identifies CD2 as a broadly expressed co‑stimulatory receptor, particularly on CD8⁺ T cells
- QL535, a trispecific PSMA × CD3 × CD2 molecule (2+1+1 TECOS format), delivers CD3 activation and CD2 co‑stimulation to enhance cytotoxicity while limiting cytokine release compared with benchmark T‑cell engagers
- QL535 demonstrates superior PSMA‑dependent killing in vitro, sustained activity under repeated stimulation, dose‑responsive tumor regression in PSMA⁺ PDX PDX models, and a favorable GLP toxicology profile in non‑human primates, supporting its clinical development for PSMA‑positive prostate cancer